Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sarepta Therapeutics announced that the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 8-6 in favor of accelerated approval for SRP-9001, a gene therapy designed to treat Duchenne muscular dystrophy (DMD). The therapy aims to deliver a gene coding for a shortened, functional form of dystrophin to muscle cells, addressing the underlying cause of DMD.
The committee's decision was based on non-clinical evidence and data from studies 101, 102, and 103, along with an integrated analysis comparing functional results to a propensity-score-weighted external control. While not binding, this vote will be considered by the FDA in its final decision, with a regulatory action date set for May 29, 2023.
SRP-9001 is currently under priority review by the FDA. Sarepta plans to commercialize the therapy in the United States upon approval, while Roche will handle distribution outside the U.S. as part of a partnership formed in December 2019.
Summary not available.